Congenital hyperinsulinism: clinical cases

Background. Congenital hyperinsulinism (CHI) is a hereditary disorder presenting with the hypersecretion of insulin by pancreatic beta cells and further development of hypoglycaemia. CHI is an orphan disease. According to the European sources, its incidence averages to 1:30,000– 1:50,000 newborns.
Clinical Cases Description. This article describes two clinical CHI cases in girls. Case 1: a girl, born on 20.06.2017, was admitted to a paediatric unit of the Children’s Territorial Clinical Hospital for a seizure syndrome. CHI was diagnosed in the age of one month. At 5 months, the girl was confirmed a focal CHI with adenomatous focus localised in pancreatic head; a subtotal head resection has been performed facilitating a compensation. The girl was discharged in a satisfactory condition for a local residence outpatient follow-up. Case 2: the patient was diagnosed with CHI at 1 year 4 months upon admission to an endocrinology unit of the Children’s Territorial Clinical Hospital. The girl was redirected to the National Medical Research Centre for Endocrinology, where CHI was confirmed and indicated for a proglycem treatment. The child was followed-up at the Centre to adjust therapy. In July 2020, a fasting test with background proglycem therapy of 2.9 mg/kg/day (62.5 mg/day) revealed a medicated compensation. The patient was discharged with improvement for a resident endocrinologist follow-up with a recommendation of proglycem at a prescribed dosage upon vital indications.
Conclusion. The clinical cases illustrate that, despite rarity and a marked heterogeneity, CHI can be timely diagnosed and properly treated in children. An adequate therapy can facilitate the disease compensation and prevent lifetime neurological complications.

1. De León D.D., Stanley C.A. Mechanisms of Disease: advances in diagnosis and treatment of hyperinsulinism in neonates. Nat. Clin. Pract. Endocrinol. Metab. 2007; 3(1): 57–68. DOI: 10.1038/ncpendmet0368

2. Lin L., Shen F., Yang Q., Yi S., Qin Z., Zhang Q., Luo J., Gao X., He S. Analysis of genetic variants in four children with congenital hyperinsulinemia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2021; 38(7): 635–638. Chinese. DOI: 10.3760/cma.j.cn511374-20200520-00358

3. Flanagan S.E., Clauin S., Bellanné-Chantelot C., de Lonlay P., Harries L.W., Gloyn A.L., Ellard S. Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum. Mutat. 2009; 30(2): 170– 180. DOI: 10.1002/humu.20838

4. Kapoor R.R., Flanagan S.E., James C., Shield J., Ellard S., Hussain K. Hyperinsulinaemic hypoglycaemia. Arch. Dis. Child. 2009; 94(6): 450–457. DOI: 10.1136/adc.2008.148171

5. Zelent D., Najafi H., Odili S., Buettger C., Weik-Collins H., Li C., Doliba N., Grimsby J., Matschinsky F.M. Glucokinase and glucose homeostasis: proven concepts and new ideas. Biochem. Soc. Trans. 2005; 33(Pt1): 306–310. DOI: 10.1042/BST0330306

6. Christesen H.B., Brusgaard K., Beck Nielsen H., Brock Jacobsen B. Non-insulinoma persistent hyperinsulinaemic hypoglycaemia caused by an activating glucokinase mutation: hypoglycaemia unawareness and attacks. Clin. Endocrinol (Oxf). 2008; 68(5): 747–755. DOI: 10.1111/j.1365-2265.2008.03184.x

7. Houghton J.A., Banerjee I., Shaikh G., Jabbar S., Laver T.W., Cheesman E., Chinnoy A., Yau D., Salomon-Estebanez M., Dunne M.J., Flanagan S.E. Unravelling the genetic causes of mosaic islet morphology in congenital hyperinsulinism. J. Pathol. Clin. Res. 2020; 6(1): 12–16. DOI: 10.1002/cjp2.144

8. Galcheva S., Demirbilek H., Al-Khawaga S., Hussain K. The Genetic and Molecular Mechanisms of Congenital Hyperinsulinism. Front Endocrinol (Lausanne). 2019; 10: 111. DOI: 10.3389/fendo.2019.00111

9. Rosenfeld E., Ganguly A., De Leon D.D. Congenital hyperinsulinism disorders: Genetic and clinical characteristics. Am. J. Med. Genet. C. Semin. Med. Genet. 2019; 181(4): 682–692. DOI: 10.1002/ajmg.c.31737

10. Lord K., De León D.D. Hyperinsulinism in the Neonate. Clin. Perinatol. 2018; 45(1): 61–74. DOI: 10.1016/j.clp.2017.10.007

11. Perminova A.A. Pathophysiological and morphological aspects of congenital hyperinsulinism. Review. Translational Medicine. 2020: 7(2); 12–20 (In Russ., English abstract). DOI: 10.18705/2311-4495-2020-7-2-12-20

12. Hardy O.T., Hernandez-Pampaloni M., Saffer J.R., Scheuermann J.S., Ernst L.M., Freifelder R., Zhuang H., MacMullen C., Becker S., Adzick N.S., Divgi C., Alavi A., Stanley C.A. Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J. Clin. Endocrinol. Metab. 2007; 92(12): 4706–4711. DOI: 10.1210/jc.2007-1637

13. Demirbilek H., Hussain K. Congenital Hyperinsulinism: Diagnosis and Treatment Update. J. Clin. Res. Pediatr. Endocrinol. 2017; 9(Suppl 2): 69–87. DOI: 10.4274/jcrpe.2017.S007

14. Sukhotskaya A.A., Bairov V.G., Nikitina I.L., Mitrofanova L.B., Perminova A.A., Ryzhkova D.V. Congenital hyperinsulinism in newborns and young children: the state of the problem and the results of surgical treatment. Medical Council. 2021; 11: 226–239 (In Russ., English abstract). DOI: 10.21518/2079-701X-2021-11-226-239

15. Sukhotskaya A.A., Bairov V.G., Nikitina I.L., Ryzhkova D.V., Mitrofanova L.B., Amidkhonova S.A. Surgical treatment of the congenital hyperinsulinism: a preliminary analysis. Russian Journal of Pediatric Surgery. 2019; 23(3): 124–127 (In Russ., English abstract). DOI: 10.18821/1560-9510-2019-23-3-124-127

16. Solntsava A., Volkava N. Treatment of Congenital Hyperinsulinism in Children: Reality and Prospects. Recipe. 2020; 23(2–3): 395–405 (In Russ., English abstract). DOI: 10.34883/PI.2020.2.2.046